Viscoelastic offers ideal protection for dense nuclei removal

Irvine, CA—The viscoelastic Vitrax (Advanced Medical Optics) is ideal for creating a wall or protective barrier for safety when removing dense nuclei during phacoemulsification, said Roger F. Steinert, MD, professor of ophthalmology and of bioengineering at the University of California, Irvine.

Related Videos
Related Content

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023
© 2023 MJH Life Sciences

All rights reserved.